2019
DOI: 10.18203/2319-2003.ijbcp20195774
|View full text |Cite
|
Sign up to set email alerts
|

Evaluating the antiproteinuric efficacy of cilnidipine in diabetic kidney disease

Abstract: Background: Diabetic kidney disease is a life threatening and disabling complication of uncontrolled diabetes mellitus. Clinical proteinuria is a well-established marker of renal dysfunction. A dual L/N-type calcium channel blocker cilnidipine dilates the afferent and efferent arterioles of the glomerulus decreasing the intraglomerular pressure and showing antiproteinuric effects. The present study was conducted to assess the antiproteinuric efficacy of cilnidipine in patients of diabetic kidney disease.Method… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…Combination therapy is mostly recommended for achieving these target BP levels in these patients [ 115 ]. It is useful for managing patients who are unresponsive to the use of a single drug agent [ 148 ]. SPC with cilnidipine (10 mg) and ARB (80 mg) was seen to be effective in reducing BP values in patients with sympathetic hyperactivity [ 39 ].…”
Section: Management/treatmentmentioning
confidence: 99%
See 1 more Smart Citation
“…Combination therapy is mostly recommended for achieving these target BP levels in these patients [ 115 ]. It is useful for managing patients who are unresponsive to the use of a single drug agent [ 148 ]. SPC with cilnidipine (10 mg) and ARB (80 mg) was seen to be effective in reducing BP values in patients with sympathetic hyperactivity [ 39 ].…”
Section: Management/treatmentmentioning
confidence: 99%
“…Combination therapy is mostly recommended for achieving these target BP levels in these patients [ 115 ]. It is useful for managing patients who are unresponsive to the use of a single drug agent [ 148 ].…”
Section: Management/treatmentmentioning
confidence: 99%